Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Effects of deep brain stimulation on functional autonomy and quality of life in Parkinson's disease: A systematic review and meta-analysis.

Created on 21 Sep 2026

Authors

Laura Culicetto, Maria Cristina De Cola, Fabiana Pia Vitiello, Giulia Marafioti, Viviana Lo Buono, Anita Maria Sophia Cusumano, Chiara Sorbera, Giuseppe Di Lorenzo, Angelo Quartarone, Silvia Marino

Published in

Journal of Parkinson's disease. Pages 1877718X261461967. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

BackgroundDeep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease (PD), primarily targeting motor complications refractory to pharmacological treatment. However, its long-term impact on functional autonomy and quality of life (QoL) remains debated.ObjectiveThis systematic review with meta-analysis aimed to evaluate the effects of STN-DBS on autonomy and QoL in people with PD.MethodsFollowing PRISMA guidelines, a systematic search of PubMed, Scopus, Embase and Web of Science was conducted to identify studies including adults with PD treated with STN-DBS and reporting measures of autonomy and/or quality of life.ResultsThirty-two studies met inclusion criteria. Meta-analyses showed effect estimates favoring DBS at 6 months (SMD = 0.83[0.38;1.29]) and at 1 year (SMD = 0.49[-0.02;0.99]) for autonomy. Similar trends were observed for QoL, with SMD = 0.60[0.49;0.71] at 6 months and SMD = 0.48[0.0;0.96] at 1 year.At 2 years, small but significant pooled effects persisted, for both autonomy SMD = 0.40[0.13;0.67] and QoL SMD = 0.25[-0.04;0.53]. However, at 5 years, pooled effects were no longer statistically significant for either autonomy SMD = 0.37[-0.55;1.29] or QoL SMD = -0.01[-0.25;0.22], indicating a progressive attenuation of benefit over time.ConclusionsSTN-DBS provides robust short- and mid-term benefits in functional autonomy and QoL in PD. Long-term outcomes are variable and influenced by disease progression and non-motor symptoms. Standardized outcome reporting, larger multicenter trials, and integration of rehabilitative and psychosocial interventions are needed to optimize benefits.

PMID:
42765824
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement